Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782555 · ClinicalTrials.gov registry record · Phase 1
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
A Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer, sponsored by ImmunoGenesis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT06782555: Recruiting Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer, sponsored by ImmunoGenesis.
NCT06782555 is a Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer that is actively recruiting participants, run by ImmunoGenesis. The registered enrollment target is 71 participants, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06782555, a Phase 1 study of Metastatic Prostate Cancer and Metastatic Pancreatic Cancer, is actively recruiting participants, sponsored by ImmunoGenesis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Conditions Studied
Interventions
- DRUG Balstilimab
- DRUG Evofosfamide
- DRUG Zalifrelimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT06782555 shows while recruiting
NCT06782555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Balstilimab is the first listed.
NCT06782555 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06782555 about?
NCT06782555 is a clinical study titled "A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab". The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma viru...
What is the current status of trial NCT06782555?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2025-01-08. Estimated completion is 2028-01.
What conditions does trial NCT06782555 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Metastatic Pancreatic Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma.
What interventions are being tested in trial NCT06782555?
The interventions under investigation include: Balstilimab (DRUG), Evofosfamide (DRUG), Zalifrelimab (DRUG).
Who is sponsoring clinical trial NCT06782555?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782555 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06782555's enrollment target sits among peer trials
71 21st of 41 higher than 21 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of AZD0754 in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
RECRUITING · Phase 1
-
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI